Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202
18/05/2026 11:51
May 18 (Reuters) - Context Therapeutics CNTX.O: CONTEXT THERAPEUTICS ENTERS INTO LICENSE AGREEMENT AMENDMENT WITH BIOATLA FOR CT-202 CONTEXT THERAPEUTICS - ANNOUNCES BUYOUT OF CT-202 FUTURE MILESTONES AND ROYALTIES CONTEXT THERAPEUTICS: AMENDMENT REMOVES ALL FUTURE MILESTONE AND ROYALTY OBLIGATIONS OWED BY COMPANY FOR CT-202 CONTEXT THERAPEUTICS - TO PAY $4.5 MILLION UPFRONT AND $2.0 MILLION BY AUG 1, 2026 FOR CT-202 LICENSE Source text: ID:nGNX9Q5ClK Further company coverage: CNTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsBrief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202
Context Therapeutics Q1 net loss widens on higher R&D costs
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding